Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Summary
The primary objective will be to evaluate the efficacy of GlycoDual in reducing fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG) levels compared to placebo after 90 days of treatment. Secondary objectives are to estimate: * the change of insulin sensitivity (HOMA-IR) * the change of uricemia after 90 days of supplementation compared to placebo. Safety objectives: Collection of the adverse events not related, related or possibly related to the study products.
Official title: Evaluation of the Efficacy of GlycoDual on Postprandial Glycemic Control and Insulin Sensitivity in Subjects With Impaired Glucose Metabolism: a Randomized, Controlled, Double-blind Study
Key Details
Gender
All
Age Range
35 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-12-01
Completion Date
2026-02-28
Last Updated
2025-12-04
Healthy Volunteers
No
Interventions
GlycoDual
GlycoDual is a food supplement developed to control post-prandial glycemia and improve insulin sensitivity in subjects with impaired glucose metabolism. GlycoDual contains maqui berry, blueberry, cocoa (rich in anthocyanins and epicatechin), and chromium picolinate, aimed at modulating the immediate glycemic response through the inhibition of α-glucosidase, stimulation of glucose transport and insulin sensitization. It also contains Gymnema sylvestre and zinc bisglycinate, aimed at supporting insulin secretion and contributing to the long-term regulation of glycemia
Placebo
Placebo